Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement

IF 0.7 Q4 UROLOGY & NEPHROLOGY
Urology Annals Pub Date : 2024-04-01 DOI:10.4103/ua.ua_15_22
Mohamed Abou-Farha, Ayman Hagras, S.A.N. Nagla
{"title":"Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement","authors":"Mohamed Abou-Farha, Ayman Hagras, S.A.N. Nagla","doi":"10.4103/ua.ua_15_22","DOIUrl":null,"url":null,"abstract":"\n \n Dutasteride is used in the treatment of benign prostate enlargement with reported many side effects.\n \n \n \n The purpose of this study is to examine how different doses of dutasteride (0.5 mg) in combination with tamsulosin affect the outcome of treatment of benign prostatic enlargement (BPE).\n \n \n \n Prospective study (phase III trial).\n \n \n \n Between April 2017 and March 2020, this randomized study was conducted on 300 patients with moderate-to-severe lower urinary tract symptoms attributable to BPE and a prostate volume of more than 40 cc. The patients were divided into three therapy groups at random (one-to-one randomization), each with 100 patients: (Group I) daily tamsulosin 0.4 mg plus dutasteride (0.5 mg). (Group II) every other day tamsulosin 0.4 mg plus dutasteride 0.5 mg. (Group III) once a week tamsulosin 0.4 mg plus dutasteride 0.5 mg.\n \n \n \n Statistical analysis was carried out with the help of the SPSS program 22. (IBM, Armonk, NY, USA). The mean and standard deviation (SD) are used to express quantitative data (SD). When comparing two means, an independent-samples t-test of significance was used. To compare more than two means, a one-way analysis of variance was utilized. For multiple comparisons between distinct variables, a post\n hoc test was performed.\n \n \n \n Patients were followed up every 3 months, with a 1-year follow-up to examine the medications’ efficacy, prostate size reduction, and erectile function. After 1 year of treatment, all groups showed significant improvement in their symptom scores. However, Groups I and II experienced a considerable reduction in prostate size after therapy, but Group III experienced no meaningful reduction. In terms of sexual dysfunction, there was a considerable shift in Group I after 12 months.\n \n \n \n Dutasteride treatment on the other day schedule has the same efficacy as the daily dose on prostate size at the same time; the other day scheduled dose has better preservation of sexual function.\n","PeriodicalId":23633,"journal":{"name":"Urology Annals","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Annals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ua.ua_15_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Dutasteride is used in the treatment of benign prostate enlargement with reported many side effects. The purpose of this study is to examine how different doses of dutasteride (0.5 mg) in combination with tamsulosin affect the outcome of treatment of benign prostatic enlargement (BPE). Prospective study (phase III trial). Between April 2017 and March 2020, this randomized study was conducted on 300 patients with moderate-to-severe lower urinary tract symptoms attributable to BPE and a prostate volume of more than 40 cc. The patients were divided into three therapy groups at random (one-to-one randomization), each with 100 patients: (Group I) daily tamsulosin 0.4 mg plus dutasteride (0.5 mg). (Group II) every other day tamsulosin 0.4 mg plus dutasteride 0.5 mg. (Group III) once a week tamsulosin 0.4 mg plus dutasteride 0.5 mg. Statistical analysis was carried out with the help of the SPSS program 22. (IBM, Armonk, NY, USA). The mean and standard deviation (SD) are used to express quantitative data (SD). When comparing two means, an independent-samples t-test of significance was used. To compare more than two means, a one-way analysis of variance was utilized. For multiple comparisons between distinct variables, a post hoc test was performed. Patients were followed up every 3 months, with a 1-year follow-up to examine the medications’ efficacy, prostate size reduction, and erectile function. After 1 year of treatment, all groups showed significant improvement in their symptom scores. However, Groups I and II experienced a considerable reduction in prostate size after therapy, but Group III experienced no meaningful reduction. In terms of sexual dysfunction, there was a considerable shift in Group I after 12 months. Dutasteride treatment on the other day schedule has the same efficacy as the daily dose on prostate size at the same time; the other day scheduled dose has better preservation of sexual function.
下尿路症状/良性前列腺增生患者减量服用度他雄胺联合α-受体阻滞剂的效果
度他雄胺用于治疗良性前列腺增生,据报道有许多副作用。 本研究旨在探讨不同剂量的度他雄胺(0.5 毫克)与坦索罗辛联用对良性前列腺增生(BPE)治疗效果的影响。 前瞻性研究(III期试验)。 2017 年 4 月至 2020 年 3 月期间,这项随机研究对 300 名因 BPE 而出现中度至重度下尿路症状且前列腺体积超过 40 毫升的患者进行了研究。患者被随机分为三个治疗组(一对一随机分组),每组 100 人:(第一组)每天服用坦索罗辛 0.4 毫克加度他雄胺(0.5 毫克)。(第二组)每隔一天服用一次坦索罗辛 0.4 毫克加度他雄胺 0.5 毫克。 第三组)每周服用一次坦索罗辛 0.4 毫克加度他雄胺 0.5 毫克。 统计分析在 SPSS 22 程序的帮助下进行。(IBM,Armonk,NY,USA)的帮助下进行了统计分析。平均值和标准差(SD)用于表示定量数据(SD)。比较两个均值时,使用独立样本 t 检验显著性。比较两个以上的均值时,采用单因素方差分析。对于不同变量之间的多重比较,则进行事后检验。 患者每 3 个月接受一次随访,随访期为 1 年,以检查药物疗效、前列腺体积缩小情况和勃起功能。治疗一年后,各组患者的症状评分均有明显改善。不过,第一组和第二组在治疗后前列腺体积明显缩小,而第三组则没有明显缩小。在性功能障碍方面,第一组在 12 个月后有了明显改善。 在同一时间内,隔日剂量的度他雄胺治疗与每日剂量的度他雄胺治疗对前列腺体积的疗效相同;而隔日剂量的度他雄胺治疗能更好地保持性功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urology Annals
Urology Annals UROLOGY & NEPHROLOGY-
CiteScore
1.20
自引率
0.00%
发文量
59
审稿时长
31 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信